title: Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas.
abstract: BACKGROUND
  Facial and intertriginous skin is more susceptible to corticosteroid-induced atrophy. Dosing regimens are needed for long-term management of corticosteroid-sensitive sites.
  
  
  OBJECTIVE
  The safety and efficacy of 0.005% fluticasone propionate ointment were assessed in the short-and long-term management of moderate to severe psoriasis of facial and intertriginous areas compared with nonfacial, nonintertriginous areas.
  
  
  METHODS
  Affected areas in 20 patients with psoriasis were treated twice daily for 2 weeks, then once daily for 2 consecutive days every week for 8 more weeks.
  
  
  RESULTS
  More than 50% improvement occurred after 2 weeks (day 15) in 100% of facial and intertriginous lesions and was maintained during long-term therapy in more than 85% of facial and intertriginous lesions. More than 50% improvement for nonfacial, nonintertriginous areas reached only 80% by day 15. Recurrence rates for facial and intertriginous areas were lower than in the nonfacial, nonintertriginous areas. Skin atrophy and telangiectasia did not occur. Facial and intertriginous sites responded more quickly to topical fluticasone propionate ointment than nonfacial, nonintertriginous skin.
  
  
  CONCLUSIONS
  Limited application of fluticasone propionate ointment over a period of 10 weeks is effective and delays lesion recurrence without causing skin atrophy in patients with moderate to severe psoriasis in areas at risk for corticosteroid application, such as facial and intertriginous areas.
authors.affiliation: Department of Dermatology, The Mount Sinai School of Medicine of New York University, New York, NY 10029, USA.
authors.forename: M G
authors.initials: MG
authors.lastname: Lebwohl
authors.forename: M H
authors.initials: MH
authors.lastname: Tan
authors.forename: S L
authors.initials: SL
authors.lastname: Meador
authors.forename: G
authors.initials: G
authors.lastname: Singer
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005148:Facial Dermatoses / Q000188:drug therapy*; D005260:Female; D000068298:Fluticasone; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D005938:Glucocorticoids; D009824:Ointments; D000068298:Fluticasone